Duration of Response to Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-cell Lymphoma by Demographic and Clinical Characteristics: Subgroup Analyses from LOTIS-2
Email this document.
Enter your email address below to send this document.